Related Experiment Videos
New approaches to trials in glomerulonephritis
Jonathan C Craig1,2, Allison Tong1,2, Giovanni F M Strippoli1,2,3,4,5,6
1Sydney School of Public Health, Sydney Medical School, University of Sydney, Sydney, Australia.
Abstract:
Randomized controlled trials are required to reliably identify interventions to improve the outcomes for people with glomerulonephritis (GN). Unfortunately, although easier, observational studies are inherently unreliable even though the findings of both study designs agree most of the time. Currently there are ∼790 trials in GN, but suboptimal design and reporting, together with small sample sizes, mean that they may not be reliable for decision making. If the history is somewhat bleak, the future looks bright, with recent initiatives to improve the quality, size and relevance of clinical trials in nephrology, including greater patient engagement, trial networks, core outcome sets, registry-based trials and adaptive designs. Given the current state of the evidence informing the care of people with GN, disruptive technologies and pervasive culture change is required to ensure that the potential of trials to improve the health of people with this complex condition is to be realized.
Insights
Reliable clinical trials are crucial for improving glomerulonephritis (GN) patient outcomes. Future research in GN requires improved trial design, larger sample sizes, and patient engagement for better evidence-based care.
Area of Science:
- Nephrology
- Clinical Trials
- Glomerulonephritis Research
Background:
- Randomized controlled trials (RCTs) are essential for identifying effective glomerulonephritis (GN) interventions.
- Observational studies, while easier, are less reliable than RCTs for clinical decision-making.
- Current GN trials (∼790) suffer from suboptimal design, reporting, and small sample sizes, limiting their reliability.
Purpose of the Study:
- To highlight the limitations of current clinical trials in glomerulonephritis (GN).
- To discuss emerging initiatives aimed at improving the quality and impact of nephrology clinical trials.
- To emphasize the need for technological and cultural shifts in GN research.
Main Methods:
- Review of existing literature on clinical trial methodology in glomerulonephritis (GN).
- Analysis of current challenges in GN trial design, sample size, and reporting.
- Discussion of recent advancements and future directions in clinical trial design for nephrology.
Main Results:
- Existing GN trials often lack the reliability needed for clinical decision-making due to design and reporting flaws.
- Numerous initiatives are underway to enhance the quality, size, and patient relevance of nephrology trials.
- These initiatives include patient engagement, trial networks, core outcome sets, registry-based trials, and adaptive designs.
Conclusions:
- Significant improvements in clinical trial methodology are necessary to advance the care of patients with glomerulonephritis (GN).
- The future of GN research hinges on embracing disruptive technologies and fostering a culture of rigorous, patient-centered trial design.
- Enhanced trial quality and relevance are critical to realizing the full potential of research in improving outcomes for this complex condition.